Kisspeptin in Women With HSDD: Randomised Crossover Trial

A placebo-controlled crossover trial investigated brain responses to erotic and facial-attraction stimuli in premenopausal women with hypoactive sexual desire disorder.

Study design

Thirty-two of 40 randomised participants completed both visits. Each received a 75-minute kisspeptin-54 or placebo infusion while functional neuroimaging, hormonal measurements and psychometric assessments were performed.

What the researchers reported

The study reported kisspeptin-associated changes in several brain regions during the stimulus tasks. Selected hippocampal and posterior-cingulate responses correlated with baseline distress or reduced sexual aversion. No adverse effects were reported during the trial.

What this result does not establish

The study assessed acute imaging and psychometric endpoints, not durable symptom improvement. Its completion sample was small, and short-term tolerability cannot establish broader or long-term safety.

This article summarizes one published study about Kisspeptin. It does not establish clinical efficacy, general safety, regulatory approval or suitability for human use. Findings should be interpreted within the model, methods and limitations of the original paper.